| 29-Sep-25 |
Buy |
Heikki Lanckriet |
749.00p | 2,000 |
£14,980.00 |
| 02-Apr-25 |
Buy |
Heikki Lanckriet |
1,205.00p | 2,400 |
£28,920.00 |
| 28-Feb-25 |
Buy |
Amy Walker |
1,120.00p | 1,151 |
£12,891.20 |
| 02-Apr-25 |
Buy |
Heikki Lanckriet |
1,205.00p | 2,400 |
£28,920.00 |
| 29-Sep-25 |
Buy |
Heikki Lanckriet |
749.00p | 2,000 |
£14,980.00 |
| 28-Feb-25 |
Buy |
Amy Walker |
1,120.00p | 1,151 |
£12,891.20 |
| Heikki Lanckriet |
1,119,688 |
£6,606,159 |
| Amy Walker |
44,016 |
£259,694 |
| Hansjörg Plaggemars |
6,667 |
£39,335 |
| Wilhelm K. T. Zours |
5,119,743 |
£30,206,484 |
| DELPHI Unternehmensberatung AG |
5,119,743 |
£30,206,484 |
| 4bb AG |
5,115,852 |
£30,183,527 |
| M&G Plc |
4,627,741 |
£27,303,672 |
| Elevage Medical Technologies Holdings |
4,627,741 |
£27,303,672 |
| Deutsche Balaton AG |
4,432,637 |
£26,152,558 |
| 2invest AG |
2,229,083 |
£13,151,590 |
| Sparta AG |
1,351,718 |
£7,975,136 |
| Latonba AG |
778,891 |
£4,595,457 |
| Franciscus De Busschere |
537,255 |
£3,169,804 |
| CEO |
Heikki Lanckriet |
| CFO |
David John Roth |
Top of Page
You are here:
research